2018-02-16 22:51:12 UTC

GREAT 5 Public Workshop


March 26—28, 2018


FDA White Oak Campus
10903 New Hampshire Avenue
Silver Spring, MD 20993


The FDA is cosponsoring a public workshop with AGA, AASLD, ACG, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) — the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT 5).

The public workshop aims to facilitate ongoing dialogue among relevant parties on issues related to alcoholic hepatitis and alcohol-associated liver disease (March 26-27) and pediatric irritable bowel syndrome (IBS) and pediatric functional constipation (March 28).

Who Should Take this Course

This workshop is intended for a diverse group of scientists responsible for the evaluation of safety and efficacy of drugs intended to treat or prevent alcohol-associated liver disease, pediatric IBS-C, and pediatric functional constipation.

The workshop is also intended for parties interested in ongoing efforts on research and development of drugs designed to treat or prevent these conditions, including patient advocates, patients and representatives from various agencies such as FDA, NIH, and others.